The focus of the Blood Cancer Program is research in the areas of acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes and myeloproliferative neoplasms.

While the team’s research is driven by the clinical need in each disease, both in vitro and in vivo fundamental discovery research enables a greater understanding of disease and therapeutic vulnerabilities which then underpins clinical translation and the delivery of personalised medicine approaches.